Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

7,345JPY
2:00am EDT
Change (% chg)

¥57 (+0.78%)
Prev Close
¥7,288
Open
¥7,350
Day's High
¥7,360
Day's Low
¥7,270
Volume
748,300
Avg. Vol
1,211,862
52-wk High
¥7,420
52-wk Low
¥5,402

Latest Key Developments (Source: Significant Developments)

Morphotek Announces Agreement To License Its Eribulin-Linker Payload To Bliss Biopharmaceutical Of China
Monday, 9 Apr 2018 10:00am EDT 

April 9 (Reuters) - Morphotek::LICENSED ITS ERIBULIN-LINKER PAYLOAD TO BLISS BIOPHARMACEUTICAL CO OF CHINA.LICENSING AGREEMENT WITH BLISSBIO INCLUDES UPFRONT PAYMENT, MILESTONES, SALES ROYALTY PAYMENTS, WHICH ARE UNDISCLOSED.BLISSBIO HAS EXCLUSIVITY OPTION TO EXPAND TERRITORY BEYOND CHINA & TO DEVELOP THERAPEUTIC ADCS TO 2 ADDITIONAL ONCOLOGY TARGETS.AGREEMENT GRANTS BLISSBIO EXCLUSIVE RIGHT TO USE ERIBULIN-LINKER PAYLOAD TO DEVELOP THERAPEUTIC ADC AGAINST ONCOLOGY TARGET FOR CHINA MARKET .  Full Article

Eisai Submits sNDA To FDA For Fycompa Pediatric Indications
Friday, 30 Mar 2018 02:53pm EDT 

March 30 (Reuters) - Eisai Inc : :EISAI SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO FDA FOR FYCOMPA® (PERAMPANEL) PEDIATRIC INDICATIONS.EISAI INC - SUBMISSION ALSO PROPOSES PEDIATRIC INDICATION FOR MONOTHERAPY, ADJUNCTIVE USE FOR PGTC SEIZURES IN CHILDREN WITH EPILEPSY.EISAI INC SAYS SNDA IS FOR BOTH FYCOMPA TABLET AND ORAL SUSPENSION FORMULATIONS.  Full Article

Nichi-Iko Pharmaceutical says business and capital alliance with Eisai
Wednesday, 28 Mar 2018 02:41am EDT 

March 28 (Reuters) - Nichi-Iko Pharmaceutical Co Ltd <4541.T>:Says it forms business and capital alliance with Eisai Co Ltd <<<4523.T>>>.Says two entities will mainly cooperate on generic drug business model reform, ecosystem construction and API application .Says it will acquire 100 percent stake in ELMED EISAI Co Ltd from Eisai Co Ltd, for 17.12 billion yen in total.Says it plans to complete stake acquisition on April 1, 2019 .  Full Article

Morphotek Announces FDA Acceptance Of IND For Cancer Treatment
Wednesday, 10 Jan 2018 09:00am EST 

Jan 10 (Reuters) - Eisai Co Ltd <4523.T>::MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202.MORPHOTEK - U.S. FDA ACCEPTED INVESTIGATIONAL NEW DRUG APPLICATION FOR MORAB-202.  Full Article

Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda
Tuesday, 9 Jan 2018 06:45am EST 

Jan 9 (Reuters) - Eisai Co Ltd <4523.T>::EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA.  Full Article

Albireo Announces Agreement With Healthcare Royalty Partners
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - Albireo Pharma Inc ::ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN.ALBIREO PHARMA INC - ‍ALBIREO SUBSIDIARY ELIGIBLE TO RECEIVE UP TO $60 MILLION UNDER AGREEMENT​.ALBIREO PHARMA INC - ‍DECISION ON JAPANESE NEW DRUG APPLICATION FOR ELOBIXIBAT EXPECTED IN FIRST HALF OF 2018​.ALBIREO PHARMA -HCR OBTAINS RIGHT TO RECEIVE ROYALTIES, SALES MILESTONES FOR ELOBIXIBAT IN JAPAN THAT MAY BE PAYABLE BY EA PHARMA, UP TO A THRESHOLD​.ALBIREO PHARMA INC - ‍ELOBIX HAS RETAINED ITS RIGHT TO RECEIVE A MILESTONE PAYMENT FROM EA PHARMA IF ELOBIXIBAT IS APPROVED BY MHLW​.ALBIREO PHARMA INC - ‍ IF SPECIFIED THRESHOLD IS REACHED, ELOBIX WILL AGAIN BECOME ELIGIBLE TO RECEIVE ROYALTIES AND SALES MILESTONES FOR ELOBIXIBAT.  Full Article

Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab
Monday, 23 Oct 2017 07:15am EDT 

Oct 23 (Reuters) - Biogen Inc :Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab.Biogen Inc - ‍Eisai has exercised its option to jointly develop and commercialize aducanumab, with Biogen continuing as development lead​.Biogen Inc - Co, Eisai to co-promote co's multiple sclerosis treatments, avonex , tysabri, tecfidera in Japan to accounts that co does not call upon​.Biogen Inc - ‍Neither party is making any upfront payments associated with exercise of aducanumab option​.Biogen Inc - ‍Under terms of agreement co will receive 55 percent of potential profits in United States and 68.5 percent of potential profits in Europe​.Biogen Inc - ‍Eisai's, Biogen's respective milestone payments under original agreement for aducanumab and BAN2401, have been eliminated​.Biogen Inc - ‍ Companies will continue to jointly develop elenbecestat (e2609), a beta amyloid cleaving enzyme (bace) inhibitor, and BAN2401​.Biogen Inc - ‍Financial terms for elenbecestat and ban2401 remain unchanged, other than eliminated BAN2401 milestone payments​.Biogen - Co to continue to lead phase 3 development of aducanumab, remain solely responsible for development costs for aducanumab until April 2018​.Biogen Inc - ‍ Under terms of agreement Eisai will receive 80 percent of potential profits in Japan and Asia excluding China and South Korea​.  Full Article

‍Morphotek announces agreement with Fujirebio Diagnostics to commercialize CA125 II assay as companion diagnostic for Farletuzumab​
Tuesday, 5 Sep 2017 10:00am EDT 

Sept 5 (Reuters) - Morphotek::Announces agreement with Fujirebio Diagnostics, Inc. to commercialize CA125 II assay as a companion diagnostic for Farletuzumab​.Agreement provides Fujirebio with worldwide license to develop, manufacture and commercialize CA125 II assay as a companion diagnostic​.  Full Article

FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures
Wednesday, 26 Jul 2017 06:41pm EDT 

July 26 (Reuters) - Eisai Co Ltd <4523.T>:FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures.Eisai - Fycompa approved for adjunctive use for pos and primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.  Full Article

Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma
Tuesday, 25 Jul 2017 07:55am EDT 

July 25 (Reuters) - Eisai Co Ltd <4523.T>::Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma.Eisai Inc - FDA submission is based on positive results of pivotal phase 3 reflect trial.  Full Article